Here’s what Cathie Wood has been buying for her flagship Ark fund!

Expert stock picker Cathie Wood has been busy again this week. So let’s take a look at the stocks Wood has been adding to her ARK Invest portfolio.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Engineer Project Manager Talks With Scientist working on Computer

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Cathie Wood is a star stock picker and the founder, CEO, and CIO of ARK Invest, an asset manager that invests in disruptive innovation. Wood gained fame in 2020 when all six ARK ETFs registered returns greater than 100%.

With the market flattening out over the past month, Wood and her ARK Invest, which has more than $40bn in assets under management, have been busy buying stocks.

So, let take look at a couple of stocks that Wood has been buying and one that she has sold.

Twilio

Twilio (NASDAQ:TWLO) is an US company, providing programmable communication tools for the telecommunications industry using its web service APIs. It makes your smart phone apps smarter by allowing them to seamlessly connect with one another.

Like many other growth stocks, Twilio’s shares have fallen, down 77% over the past 12 months.

However, this belies some fairly positive performance data. In its last reported quarter, Twilio’s organic revenue rose 35%, above expectations. But net income for the quarter was -$221m. So there’s clearly some distance to go before this company becomes profitable.

In June, Scotiabank initiated coverage of Twilio at “outperform“. The brokerage set a target price of $215, implying 162% upside from today’s share price.

Wood bought more Twilio stock on Thursday.

Exact Sciences

Exact Sciences (NASDAQ:EXAS) is a molecular diagnostics company specialising in the detection of early stage cancers. There’s clearly huge potential for the company’s products, with cancer one of the biggest killers in the developed world.

The company received a boost last week when a new Medicare fee schedule was proposed. Previously, if individuals received a positive result with Exact Sciences’s Cologuard, they would have to pay for a follow-up colonoscopy. But under the new proposal, that fee is scrapped. Several analysts think this could boost the utility of Cologuard.

The stock is down a whopping 58% over the past 12 months. Whether the product will truly catch on is an issue for me.

Wood bought more Exact Sciences stock on Thursday.

CRISPR Therapeutics

Wood sold shares in CRISPR Therapeutics (NASDAQ:CRSP) on Wednesday. The stock is up 33% over the past month but remains down 34% over the past year.

The stock has been pretty volatile in recent months. The firm recently held an innovation day to showcase its entire drug pipeline. However, CRISPR’s kidney cancer trial data did not impress investors and the stock tanked.

However, it’s been gaining since then on the back of news that the firm will be able to commercialise the first ever CRISPR gene therapy, a functional cure for TDT and sickle cell disease, in the coming months. 

While the company didn’t generate traditional sales in 2021, it generated plenty of revenue in research milestone agreements. In fact, it has a price-to-sales ratio of 5.8 for the trailing 12 months versus an industry average of 4.1. 

What’s does this mean for me?

I predominately invest in FTSE stocks, but I keep an eye on Wood’s portfolio. CRISPR Therapeutics is a stock I had been looking to add to my portfolio, but I was put off by the early stage cancer data back in June.

I haven’t had much exposure to Exact Sciences or Twilio, but I’d be willing to add the latter to my portfolio.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James Fox has no position in any of the shares mentioned. The Motley Fool UK has recommended CRISPR Therapeutics. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Will it be too late to buy Nvidia stock in March?

NVIDIA stock is up more than 60% since the start of 2024. Our writer considers whether it might still be…

Read more »

Typical street lined with terraced houses and parked cars
Investing Articles

Why did Direct Line shares just soar 27%?

Direct Line shares have jumped more than a quarter in the course of today's trading session. Our writer explains why…

Read more »

Close-up of British bank notes
Investing Articles

These 2 shares are Dividend Aristocrats. Which should I buy this March?

Our writer likes the business model of this pair of FTSE 100 Dividend Aristocrats. So why would he only consider…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

I bought 49 Unilever shares in June. Here’s what they’re worth today

Harvey Jones bought a modest amount of Unilever shares last summer hoping the stock would soon recover. He's having to…

Read more »

BUY AND HOLD spelled in letters on top of a pile of books. Alongside is a piggy bank in glasses. Buy and hold is a popular long term stock and shares strategy.
Investing Articles

I reckon these shares, potentially 20% undervalued, are Warren Buffett’s type of investment

Oliver Rodzianko thinks Games Workshop is an absolutely stellar investment. As it's potentially undervalued, he reckons Warren Buffett would agree.

Read more »

Calendar showing the date of 5th April on desk in a house
Investing Articles

Great investing habits that can boost my Stocks and Shares ISA

Forget complicated calculations and financial jargon! Our writer uses a few simple habits to build wealth inside his Stocks and…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Why has the St. James’s Place share price crashed 30%, after FY results?

The St. James's Place share price has just fallen off a cliff. What could have gone wrong in 2023 that's…

Read more »

Family in protective face masks in airport
Investing Articles

Here’s how much I’d have if I’d bought 1,000 Rolls-Royce shares 10 years ago

Rolls-Royce shares may be flying high this year but that wasn't always the case. I'm calculating how much I'd have…

Read more »